PDGFRB Fusion

CI-VAR-00001186Explore in graph →CIViC 568

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 5 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like1
v::PDGFRB Fusion	(diagnostic)	Diagnostic	A	Supports Positive	4	submitted	EID7022 This study showed that, when detected in the context of B-cell lymphoblastic leukemia/lymphoma (B-ALL), PDGFRB fusions with different partner genes are associated with Ph-like molecular subtype of B-A… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC	civic
Chronic Myelomonocytic Leukemia1
v::PDGFRB Fusion	(diagnostic)	Diagnostic	A	Supports Negative	5	accepted	EID1426 The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusi… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Hematopoietic and Lymphoid Cell Neoplasm1
v::PDGFRB Fusion	(diagnostic)	Diagnostic	A	Supports Positive	5	accepted	EID1434 The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated wit… (full text at CIViC) PMID 27069254 · Arber et al., 2016 · Open in CIViC	civic

Myeloproliferative Neoplasm2
v::PDGFRB Fusion	Imatinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID1498 Twelve patients with BCR-ABL-negative chronic myeloproliferative disease and reciprocal translocations involving PDGFRB received imatinib for a median of 47 months (range, 0.1-60 months). Eleven had p… (full text at CIViC) PMID 16960151 · David et al., 2007 · Open in CIViC	civic
v::PDGFRB Fusion	Imatinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11272 In this phase II, open-label, single-arm trial, 106 patients with 40 different malignancies were enrolled (78.5% solid tumours, 21.5% hematologic malignancies), including seven with myeloproliferative… (full text at CIViC) PMID 18451237 · Heinrich et al., 2008 · Open in CIViC	civic

Systemic Mastocytosis1
NOT KIT D816V AND v::PDGFRB Fusion	Imatinib Mesylate	Predictive	C	Supports Sensitivity Response	3	submitted	EID11368 In this case report, a 61 yearl-old male patient was diagnosed with systemic mastocytosis (SM). Genetic screening for KIT mutaitons, including the D816V mutation, was negative. FISH analysis showed a … (full text at CIViC) PMID 18166785 · Lahortiga et al., 2008 · Open in CIViC	civic